Cannacord recently attended the EuroPCR 2015 scientific sessions in Paris, and analysts followed up on the event by releasing a report this week on four of their top biotech stock picks. According to the report, the event provided updates that were “testament to our belief that the interventional cardiology arena will be one of the most dynamic in med-tech for years to come.”

Here’s a quick takeaway summary of what Cannacord saw at the conference.

TMVR Takes Center Stage

Analysts note that the sessions discussing transcatheter mitral valves (TMVR) were especially crowded. The unproven devices are still very early in their development, and many questions remain unanswered at this point. However, analysts explain that the need to find a less-invasive treatment for mitral regurgitation is “inarguable,” and some form of TMVR could eventually prove to be a viable solution.

TAVI Still Showing Potential

Despite the excitement surrounding TMVR, transcatheter aortic valve implantation (TAVI) still shows…

Read the rest of this article (and all my other articles) for free on Benzinga by clicking here

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!